Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization Sort descending
Dec
13
2021
Health Law Policy Heading Into 2022 At The ABA Health Law Summit Sheppard, Mullin, Richter & Hampton LLP
May
31
2014
Developer-Prepared Cost Comparisons Can Show Economic Infeasibility Under CEQA - California Environmental Quality Act Sheppard, Mullin, Richter & Hampton LLP
Jan
10
2022
CMS’ Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs Sheppard, Mullin, Richter & Hampton LLP
Jan
13
2022
Day Three Notes for the 40th Annual J.P. Morgan Healthcare Conference, 2022 Sheppard, Mullin, Richter & Hampton LLP
Apr
12
2022
No April Fools: Starting April 1st, Cannabis Operators Face CEQA Compliance Requirements for State Licenses Sheppard, Mullin, Richter & Hampton LLP
Nov
3
2014
Agricultural Cooperative Antitrust Litigation Continues to Mushroom Sheppard, Mullin, Richter & Hampton LLP
Jan
5
2015
New FDA Draft Guidance on REMS and Bioequivalence Studies: Does New Procedure Secure ANDA Applicants The Right to Obtain Samples? Sheppard, Mullin, Richter & Hampton LLP
Jul
5
2022
Recap of AHLA’s Annual Meeting Sheppard, Mullin, Richter & Hampton LLP
Feb
12
2020
Federal Circuit Revolutionizes Country of Origin Analysis for Pharmaceuticals Sheppard, Mullin, Richter & Hampton LLP
Jun
16
2023
DOJ Continues to Discuss Updates to Compliance Program Guidance and Corporate Enforcement Policies Sheppard, Mullin, Richter & Hampton LLP
Mar
31
2020
Personal Protective Equipment & Ventilators: How FDA Is Increasing Supply for the US Healthcare System Sheppard, Mullin, Richter & Hampton LLP
Oct
17
2023
Tele-Prescribing Flexibilities Extended Again in Second Temporary Rule Sheppard, Mullin, Richter & Hampton LLP
Jun
23
2020
FDA Issue Guidance on Manufacturing Drugs, APIs during COVID-19 Sheppard, Mullin, Richter & Hampton LLP
Nov
21
2023
Voluntary Self-Disclosure of FCPA Violations Following Acquisition Avoids Corruption Charges Sheppard, Mullin, Richter & Hampton LLP
Dec
11
2020
It’s Not Pop Secret, Ninth Circuit Affirms that Plaintiff Didn’t Have a Leg to Stand On Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2024
Health-e Law Episode 8: What We Heard at HIMSS 2024 with Michael Orlando & Carolyn Metnick [Podcast] Sheppard, Mullin, Richter & Hampton LLP
Jul
2
2010
US Patent Office Expands Green Technology Accelerated Examination Program - More categories of invention are now eligible for expedited processing Sheppard, Mullin, Richter & Hampton LLP
Feb
8
2011
The Tax Relief, Unemployment Insurance Reauthorization and Job Creation Act of 2010 and its effect on the Energy Sector Sheppard, Mullin, Richter & Hampton LLP
Dec
11
2017
Texas Telemedicine Saga Finally Over? The Texas Medical Board Substantially Revises Telemedicine Regulations Sheppard, Mullin, Richter & Hampton LLP
Dec
19
2011
Taking a Cue From Brazil's Sustainable Development Practices Past and Present Sheppard, Mullin, Richter & Hampton LLP
Dec
10
2013
New “Potentially Feasible” Alternative Does Not Trigger Draft Environmental Impact Report (EIR) Recirculation Unless Considered “Significant New Information”; No Findings Needed to Reject Alternative As Infeasible Sheppard, Mullin, Richter & Hampton LLP
Dec
13
2021
Debate Continues Around Scope of Practice Expansion for APPs Sheppard, Mullin, Richter & Hampton LLP
Mar
21
2019
Federal Circuit Weighs in on Patent Subject-Matter Eligibility of Dietary Supplements Sheppard, Mullin, Richter & Hampton LLP
Apr
18
2022
Sow What Now?: Cal. Hispanic Chambers of Commerce et. al. v. Ross et. al., The U.S. Supreme Court, and California’s Proposition 12 Sheppard, Mullin, Richter & Hampton LLP
Jul
5
2022
CMS Adopts Major Changes to LTC Facility Surveyor Guidance Sheppard, Mullin, Richter & Hampton LLP
Feb
12
2015
Interface without Regulation – FDA Deregulates MDDS and Related Technologies Sheppard, Mullin, Richter & Hampton LLP
Jun
10
2015
NDRC Issued Opinions and Notice on Drug Price Reform: National Development and Reform Commission Sheppard, Mullin, Richter & Hampton LLP
Mar
17
2020
FDA Grants COVID-19 Diagnostic Emergency Use Authorizations, And Other Recent FDA Actions to Address COVID-19 Sheppard, Mullin, Richter & Hampton LLP
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins